NCT06586515 Cancer Clinical Trial

PIPELINE > TRIAL OVERVIEW

Phase

Enrolling

A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors^a

Have histologically or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA
Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
Must be able to swallow tablets
Select cohorts must have received ≥1 prior line of systemic chemotherapy for advanced or metastatic disease

Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Participants with asymptomatic or treated CNS disease may be eligible
Have any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1 at the time of starting trial treatment, except for alopecia, peripheral neuropathy, and ongoing endocrinopathies controlled on appropriate replacement therapy
Have significant cardiovascular disease such as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction, or uncontrolled or symptomatic arrhythmias
Have known active hepatitis B, hepatitis C, or untreated HIV
Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
Have other active malignancy unless in remission with life expectancy of >2 years

This clinical trial is currently being conducted in the United States and Japan.

Administered orally.

Administered intravenously.

For information on trial enrollment, locations, and more, call 1-800-545-5979.

or visit www.clinicaltrials.gov for more information on this trial